The global flow cytometry in oncology and immunology market was valued at $1,653.2 million in 2021 and is anticipated to reach $5,287.4 million by 2032, witnessing a CAGR of 11.39% during the forecast period 2022-2032.

The market is driven by factors such as the increasing burden of cancer, expansion of applications in flow cytometry for research activities, innovation in flow cytometry leading to the use of next-generation flow cytometers, and the increasing use of flow cytometry in the identification and diagnosis of immune-deficiency diseases.

Market Lifecycle Stage

The global flow cytometry in the oncology and immunology market is in the developed phase. The increasing research for flow cytometry for the detection of solid tumors and the leveraging of public-private initiatives to advance R&D in the field of immunology and oncology research are some of the major opportunities in the global flow cytometry in oncology and immunology market.

Impact of COVID-19

COVID-19 had a minimal impact on the global flow cytometry in oncology and immunology market. The initial breakout of the pandemic led to an increase in the use of reagents of flow cytometry in research activities and clinical trials. However, the manufacturers witnessed a loss in 2020 due to COVID-19 restrictions and preventive actions such as a reduction in supply chain and sales.

Also, there was a significant shift observed toward research activities for treating and diagnosing COVID-19, which resulted in a halt in research activities for oncology using flow cytometry. Besides these minimal impacts, flow cytometry in oncology and immunology is expected to overcome the impact in the forecast period 2022-2032.

Market Segmentation:

Segmentation 1: by Offering

• Products
o Instruments
o Reagents and Consumables
o Software
• Services

The global flow cytometry in oncology and immunology market (by offering) is expected to be dominated by the products segment.

Segmentation 2: by Technology

• Cell-Based Flow Cytometry
• Bead-Based Flow Cytometry

The global flow cytometry in oncology and immunology (by technology) is expected to be dominated by the cell-based flow cytometry segment.

Segmentation 3: by Type

• Immunology
• Oncology

The global flow cytometry in oncology and immunology market (by type) is dominated by the oncology segment.

Segmentation 4: by Application

• Translational Research
• Clinical Research

The global flow cytometry in oncology and immunology market (by application) is dominated by the translational research segment.

Segmentation 5: by End User

• Hospitals, Diagnostic Laboratories, and Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations
• Others

The global flow cytometry in oncology and immunology market (by end user) is dominated by the hospitals, diagnostic laboratories, and reference laboratories segment.

Segmentation 6: by Region

• North America – U.S., Canada
• Europe – Germany, France, U.K., Italy, Spain, Netherlands, Rest-of-Europe
• Asia-Pacific – Japan, China, India, Australia, South Korea, Singapore, Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World

The global flow cytometry in oncology and immunology market (by region) is dominated by the North America segment.

Recent Developments in the Global Flow Cytometry in Oncology and Immunology Market

• In February 2022, Becton, Dickinson and Company acquired Cytognos, S.L. Through this acquisition, the company expanded its flow cytometry portfolio and gained the expertise of ~80 scientists and professionals at Cytognos S.L.

• In September 2022, Becton, Dickinson and Company launched BD Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines, including immunology, virology, oncology, and infectious disease monitoring.

• In September 2021, Beckman Coulter, a wholly owned subsidiary of Danaher Corporation, launched its new CytoFLEX flow cytometry platform, which is expected to open new avenues for cancer researchers with respect to single-cell analysis. This new system launched by the company offers powerful analytical performance in a benchtop instrument, which offers high sensitivity.

• In February 2021, Thermo Fisher Scientific Inc. acquired the cell sorting technology assets of Propel Labs, which is expected to broaden Thermo Fisher’s flow cytometry and cell analysis portfolio.

• In December 2020, Thermo Fisher Scientific Inc. acquired Phitonex, Inc., a pioneer in the field of spectral dye platforms for high-resolution biological applications, including oncology and immunology. With the acquisition of the company, Thermo Fisher Scientific Inc. is expected to offer greater flow cytometry capabilities to meet evolving customer demands for cell and protein analysis research.

• In January 2020, Luminex Corporation acquired Merck’s flow cytometry business portfolio for $75 million, further enabling the company to effectively enhance its existing offerings related to flow-based detection instruments. The company’s newly acquired FCM portfolio includes Guava and Amnis product portfolios.

Demand – Drivers and Limitations

Following are the drivers for the global flow cytometry in oncology and immunology market:

• Increasing Burden of Cancer is One of the Major Propelling Factors for the Innovation of Novel Technologies in Flow Cytometry
• Expansion of Applications in Flow Cytometry for Research Activities Propels its Demand in the Market
• Innovation in Flow Cytometry Leading to Use of Next-Generation Flow Cytometers
• Increasing Use of Flow Cytometry in Identification and Diagnosis of Immune-Deficiency Diseases

The market is expected to face some limitations as well due to the following challenges:

• High Cost of the Products of the Flow Cytometry Equipment Restraining the Adoption of the Devices in Emerging Economies
• False Negative and Positive Antibody Responses Can Hinder the Adoption of Flow Cytometry

How can this report add value to an organization?

Offerings: The offerings segment helps the reader understand the different types of flow cytometry offerings available in the market. Moreover, the study provides the reader with a detailed understanding of products that fall under the two main segments, i.e., products and services.

Growth/Marketing Strategy: The global flow cytometry in oncology and immunology market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, and regulatory and legal approvals.

The favored strategy for the companies has been new product offerings to strengthen their position in the market. For instance, in June 2022, Becton, Dickinson and Company launched its new cell sorting technology at the International Society for Advancement of Cytometry (ISAC). Using this technology can help in sorting cells at a very fast speed during flow cytometry.

Competitive Strategy: The key players in the global flow cytometry in oncology and immunology market analyzed and profiled in the study involve established and emerging players that offer different products for flow cytometry.

Moreover, a detailed competitive benchmarking of the players operating in the global flow cytometry in oncology and immunology market has been done to help the reader understand the ways in which players stack against each other, presenting a clear market landscape.

Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, mergers, and acquisitions will help the reader understand the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the players in this market are:

• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Cytek Biosciences, Inc.
• Danaher Corporation
• DiaSorin S.p.A (Luminex Corporation)
• Enzi Biochem Inc.
• Laboratory Corporation of America Holdings
• Merck KGaA
• Miltenyi Biotec
• NeoGenomics Laboratories, Inc.
• OPKO Health, Inc.
• Sony Group Corporation
• Thermo Fisher Scientific Inc

The post Flow Cytometry in Oncology and Immunology Market – A Global Market and Regional: Focus on Offering, Technology, End User, Type, Application, and Country – Analysis and Forecast, 2022-2032 first appeared on CRI Report.

Market Segmentation

• Vector Type – Viral Vector and Non-Viral Vector
• Disease – Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
• Application – Gene Therapy, Vaccinology, Cell Therapy, and Other Applications

Regional Segmentation

• North America: U.S., Canada
• Europe: Germany, U.K., France, Italy, Switzerland, Belgium, Spain, and Rest-of-Europe
• Asia-Pacific: China, India, Japan, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
• Rest-of-the-World

Market Growth Drivers

• Rapid Uptake of Viral Vector to Develop Innovative Therapies
• Increasing Number of Clinical Studies for the Development of Gene Therapy
• Favorable Funding Scenario for Vector-Based Therapies
• Increasing Adoption of Nucleic Acid Therapeutics
• Rise in Synergistic Activities in the Market

Market Challenges

• Unaffordable Cost of Gene Therapy
• High Manufacturing Cost of Viral Vectors
• Complications Associated with Large-Scale Production of Viral Vectors
• Low Transfection Efficiency

Market Opportunities

• Rise in Demand for Synthetic Genes
• Emergence of Next-Generation Vectors
• Limitation of Viral Vectors

Key Companies Profiled

Boehringer Ingelheim, Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Genscript Biotech Corporation, Lonza Group AG, Merck KGaA Inc., Oxford Biomedica plc, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., Wuxi AppTec, Acuitas Therapeutics, Evonik Industries AG, Exelead, Inc., Entos Pharmaceuticals, Genevant Sciences GmbH, T&T Scientific Corporation, Moderna, Inc., CureVac N.V.

Key Questions Answered in this Report:

• What is a vector, and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors?
• What are the major advancements in viral and non-viral vector manufacturing? What are the key trends of the global viral and non-viral vector manufacturing market? How is the market evolving, and what is its future scope?
• What are the major drivers, challenges, and opportunities of the global viral and non-viral vector manufacturing market?
• What are the key developmental strategies implemented by the key players of the global viral and non-viral vector manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
• What is the regulatory scenario of the global viral and non-viral vector manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral and non-viral vector manufacturing products?
• What are major milestones in patenting activity in the global viral and non-viral vector manufacturing market?
• What was the market size of the global viral and non-viral vector manufacturing market in 2020, and what is the market size anticipated to be by 2031? What is the expected growth rate of the global viral and non-viral vector manufacturing market during the forecast period 2021-2031?
• What is the global market size for manufacturing different types of viral and non-viral vectors available in the global viral and non-viral vector manufacturing market? What are the key trends of the market with respect to different vectors, and which vector type is expected to dominate the market in 2031?
• What are the different disease areas where non-viral vectors and viral vectors are employed in the global viral and non-viral vector manufacturing market? Which disease type dominated the market in 2020 and is expected to dominate in 2031?
• What are the different applications associated with the viral vector and non-viral vector manufacturing? What was the contribution of each of the application areas in the global viral and non-viral vector manufacturing market in 2020, and what is it expected in 2031?
• Which region is expected to contribute the highest sales in the global viral and non-viral vector manufacturing market during the period 2021-2031? Which region and country carries the potential for the significant expansion of key companies for different viral and non-viral vector manufacturing? What are the leading countries of different regions that contribute significantly toward the growth of the viral and non-viral manufacturing market?
• What are the key players of the global viral and non-viral vector manufacturing market, and what are their roles in the market? What were the market shares of the key players in 2020?

Market Overview

The advent of advanced therapies, including gene therapy and cell therapy, which employ the use of vectors, has created a huge impact in the field of medicine in the past few decades.

Therapies that require genetic modification, including the introduction of therapeutic deoxyribonucleic acid (DNA)/gene into a patient’s body or cell, demonstrated tremendous potential for treating several fatal diseases, including cancer, Alzheimer’s disease, Parkinson’s disease, and rheumatoid arthritis, among others.

Promising results displayed by these vector-based therapies in several preclinical and clinical studies have further emphasized the development and standardization of various viral and non-viral vectors to address unmet medical needs.

The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.

Known to reduce the cost of treatment and help decrease repeated administration of medications, viral vectors, and non-viral vectors have gained significant attention globally as a novel therapeutic approach for treating various critical diseases, thereby promoting a surge of investments in drug development and commercialization.

Growing prominence of gene and cell therapy products (that utilize vectors) and increasing funding activities driving research related to vector-based therapies are the key driving factors fuelling the growth of the global viral and non-viral vector manufacturing market.

Moreover, rising incidences of genetic disorders, cancers, and infectious diseases, coupled with the increasing number of clinical studies and robust pipeline of gene and cell therapy products as well as vector-based vaccines, are the additional driving factors encouraging market growth.

Competitive Landscape

The global viral and non-viral vector manufacturing market comprises well-established and newly emerging companies. Several companies are attempting to enter the market and sustain the competition by adopting synergistic activities and expanding their business by launching manufacturing capacities or developing proprietary viral and non-viral vector platforms.

In the past three years (2018-2020), the key market players of the global viral and non-viral vector manufacturing market witnessed majorly synergistic activities, business expansion, and funding activities. The inclination of companies toward synergies suggests that the companies are collaborating with viral and non-viral vector manufacturers to develop novel cell therapies, gene therapies, and vaccines for various diseases. The expansion of manufacturing capacities suggests that the companies are trying to fulfill the increased demand for vectors for cell and gene therapies.

Related Report: Global Viral Clearance Services Market 2029

Related Report: Anti-Viral Fabric Market – A Global and Regional Analysis: Focus on Products and Region Assessment – Analysis and Forecast, 2021- 2026

The post Global Viral and Non-Viral Vector Manufacturing Market: Focus on Vector Type, Application, Disease and Region – Analysis and Forecast, 2021-2031 first appeared on CRI Report.